Klas M. Kellerborg

Klas M. Kellerborg

Lund, M, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Budget impact models for lung cancer interventions: A systematic literature review.

Budget impact models for lung cancer interventions: A systematic literature review.

Journal: Journal of managed care & specialty pharmacy

Published: August 30, 2024

Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life.

Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life.

Journal: Movement disorders clinical practice

Published: September 07, 2022

The Relationship between PDQ-8 and Costs in Parkinson's Disease-A Swedish Register-Based Study.

The Relationship between PDQ-8 and Costs in Parkinson's Disease-A Swedish Register-Based Study.

Journal: Movement disorders clinical practice

Published: May 25, 2022

High risk of developing dementia in Parkinson's disease: a Swedish registry-based study.

High risk of developing dementia in Parkinson's disease: a Swedish registry-based study.

Journal: Scientific reports

Published: May 16, 2022

Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson's disease.

Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson's disease.

Journal: Scientific reports

Published: September 24, 2021

Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson's Disease: A Swedish Register-Based Study in 1823 Observations.

Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson's Disease: A Swedish Register-Based Study in 1823 Observations.

Journal: PharmacoEconomics

Published: June 05, 2021

Parkinson's disease in Sweden-resource use and costs by severity.

Parkinson's disease in Sweden-resource use and costs by severity.

Journal: Acta neurologica Scandinavica

Published: May 28, 2021

Estimating the costs of non-medical consumption in life-years gained for economic evaluations.

Estimating the costs of non-medical consumption in life-years gained for economic evaluations.

Journal: Social science & medicine (1982)

Published: February 21, 2021

Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands.

Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands.

Journal: Vaccine

Published: November 01, 2020

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model.

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: October 08, 2020

Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0.

Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: January 20, 2020

Distributional consequences of including survivor costs in economic evaluations.

Distributional consequences of including survivor costs in economic evaluations.

Journal: Health economics

Published: November 12, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026